Efficacy and safety profile of AU7R-104, a small molecule targeting CD47/SIRPα pathway

Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients (pts) with advanced solid tumor and Hodgkin

In vivo anti-tumor efficacy with a dual degrader of SMARCA2 and SMARCA4

Oral Immune Checkpoint Antagonists Dually Targeting TIGIT and PD-1 pathways for Cancer Therapy

Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients (pts) with advanced solid tumor and Hodgkin

Potent anti-tumor activity correlated with inhibition of DNA damage response genes with highly selective and orally bioavailable CDK12 covalent inhibitors

Identification of SMARCA2/4 degraders for the treatment of SMARCA4-mutant and other cancers (SMARCA2/4 degraders)

Preclinical In vivo evaluation of efficacy, pharmacokinetics and pharmacodynamics of novel PRMT5 inhibitors in multiple tumor models (PRMT5i)

Combination efficacy and safety profile of an orally bioavailable small molecule agent targeting CD47/SIRPα axis (CD47 antagonists)

Preclinical evaluation of PD and efficacy of novel potent selective and orally bioavailable CDK12 covalent inhibitors in TNBC model (Covalent selective, CDK12i)